PortfoliosLab logoPortfoliosLab logo
IOVA vs. MATW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IOVA vs. MATW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Iovance Biotherapeutics, Inc. (IOVA) and Matthews International Corporation (MATW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IOVA achieves a 48.72% return, which is significantly higher than MATW's 1.87% return. Over the past 10 years, IOVA has underperformed MATW with an annualized return of -6.39%, while MATW has yielded a comparatively higher -4.38% annualized return.


IOVA

1D
3.84%
1M
-1.22%
YTD
48.72%
6M
46.04%
1Y
105.05%
3Y*
-20.47%
5Y*
-30.33%
10Y*
-6.39%

MATW

1D
-0.91%
1M
-2.39%
YTD
1.87%
6M
2.30%
1Y
29.23%
3Y*
-9.69%
5Y*
-2.96%
10Y*
-4.38%
*Multi-year figures are annualized to reflect compound growth (CAGR)

IOVA vs. MATW - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
IOVA
Iovance Biotherapeutics, Inc.
48.72%-63.11%-8.98%27.23%-66.53%-58.86%67.63%212.77%10.62%15.11%
MATW
Matthews International Corporation
1.87%-1.50%-21.25%23.36%-14.50%27.72%-20.49%-3.95%-21.88%-30.53%

Correlation

The correlation between IOVA and MATW is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.23

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Oct 15, 2010

0.17

Fundamentals

EPS

IOVA:

-$0.93

MATW:

$0.41

PS Ratio

IOVA:

5.42

MATW:

0.51

Total Revenue (TTM)

IOVA:

$285.61M

MATW:

$1.21B

Gross Profit (TTM)

IOVA:

$327.04M

MATW:

$432.86M

EBITDA (TTM)

IOVA:

-$325.45M

MATW:

$201.65M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IOVA vs. MATW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IOVA
IOVA Risk / Return Rank: 7474
Overall Rank
IOVA Sharpe Ratio Rank: 7474
Sharpe Ratio Rank
IOVA Sortino Ratio Rank: 7979
Sortino Ratio Rank
IOVA Omega Ratio Rank: 7474
Omega Ratio Rank
IOVA Calmar Ratio Rank: 7575
Calmar Ratio Rank
IOVA Martin Ratio Rank: 6868
Martin Ratio Rank

MATW
MATW Risk / Return Rank: 6969
Overall Rank
MATW Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
MATW Sortino Ratio Rank: 6666
Sortino Ratio Rank
MATW Omega Ratio Rank: 6262
Omega Ratio Rank
MATW Calmar Ratio Rank: 7474
Calmar Ratio Rank
MATW Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IOVA vs. MATW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and Matthews International Corporation (MATW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IOVAMATWDifference
Sharpe ratioReturn per unit of total volatility

+0.18

Sortino ratioReturn per unit of downside risk

+0.68

Omega ratioGain probability vs. loss probability

1.24

1.17

+0.08

Calmar ratioReturn relative to maximum drawdown

1.94

1.85

+0.09

Martin ratioReturn relative to average drawdown

3.05

4.26

-1.21

IOVA vs. MATW - Sharpe Ratio Comparison

The current IOVA Sharpe Ratio is 1.04, which is comparable to the MATW Sharpe Ratio of 0.87. The chart below compares the historical Sharpe Ratios of IOVA and MATW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

IOVA vs. MATW - Drawdown Comparison

The maximum IOVA drawdown since its inception was -99.37%, which is greater than MATW's maximum drawdown of -75.27%. Use the drawdown chart below to compare losses from any high point for IOVA and MATW.


Loading charts...

Drawdown Indicators


IOVAMATWDifference

Max Drawdown

Largest peak-to-trough decline

-99.37%

-75.27%

-24.10%

Max Drawdown (1Y)

Largest decline over 1 year

-54.41%

-15.87%

-38.54%

Max Drawdown (3Y)

Largest decline over 3 years

-90.50%

-58.68%

-31.82%

Max Drawdown (5Y)

Largest decline over 5 years

-93.99%

-58.68%

-35.31%

Max Drawdown (10Y)

Largest decline over 10 years

-96.84%

-75.27%

-21.57%

Current Drawdown

Current decline from peak

-97.45%

-55.94%

-41.51%

Average Drawdown

Average peak-to-trough decline

-84.18%

-24.75%

-59.43%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.61%

6.88%

+27.73%

Volatility

IOVA vs. MATW - Volatility Comparison

Iovance Biotherapeutics, Inc. (IOVA) has a higher volatility of 25.62% compared to Matthews International Corporation (MATW) at 8.62%. This indicates that IOVA's price experiences larger fluctuations and is considered to be riskier than MATW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IOVAMATWDifference

Volatility (1M)

Calculated over the trailing 1-month period

25.62%

8.62%

+17.00%

Volatility (6M)

Calculated over the trailing 6-month period

64.08%

21.67%

+42.41%

Volatility (1Y)

Calculated over the trailing 1-year period

101.54%

33.95%

+67.59%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

89.88%

36.34%

+53.54%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.44%

36.97%

+44.47%

Dividends

IOVA vs. MATW - Dividend Comparison

IOVA has not paid dividends to shareholders, while MATW's dividend yield for the trailing twelve months is around 3.89%.


PositionTTM20252024202320222021202020192018201720162015
IOVA
Iovance Biotherapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
MATW
Matthews International Corporation
3.89%3.85%4.37%2.54%2.92%2.36%2.87%2.12%1.90%1.33%0.81%1.01%

Financials

IOVA vs. MATW - Financials Comparison

This section allows you to compare key financial metrics between Iovance Biotherapeutics, Inc. and Matthews International Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00100.00M200.00M300.00M400.00M500.00M20222023202420252026
71.43M
258.62M
(IOVA) Total Revenue
(MATW) Total Revenue
Values in USD except per share items

Frequently Asked Questions


IOVA and MATW have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IOVA has higher volatility (25.62%) compared to MATW (8.62%). In terms of maximum drawdown, IOVA dropped -99.37% vs MATW's -75.27%.

IOVA currently has the higher Sharpe Ratio (1.04 vs 0.87), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IOVA and MATW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer